TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02411630

Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil
Description: ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed.
Study: NCT02244541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral
Description: 30 mg hard gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 Oral
Description: 50 mg hard gelatin capsule
Study: NCT02638116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
Study: NCT03482622

Intervention type: DIAGNOSTIC_TEST
Intervention: Fast Raman
Description: Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
Study: NCT02859922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube Suction Disposable
Description: Laryngeal Tube Suction Disposable

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme Laryngeal Mask Airway
Description: Supreme Laryngeal Mask Airway
Study: NCT00771914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza 4 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza 4 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza 4 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza 4 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both Aspirin and Lovaza
Description: Lovaza 4 grams plus aspirin 81 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both Aspirin and Lovaza
Description: Lovaza 4 grams plus aspirin 81 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both Aspirin and Lovaza
Description: Lovaza 4 grams plus aspirin 81 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both Aspirin and Lovaza
Description: Lovaza 4 grams plus aspirin 81 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule resembling fish oil and a tablet resembling aspirin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule resembling fish oil and a tablet resembling aspirin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule resembling fish oil and a tablet resembling aspirin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule resembling fish oil and a tablet resembling aspirin
Study: NCT01003301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
Study: NCT04045860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy
Description: A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Standard of care is currently observation
Study: NCT04937985

Intervention type: OTHER
Intervention: Performance Tests
Description: Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
Study: NCT05288816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
Study: NCT02300207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic acupuncture treatment instrument
Description: Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
Study: NCT04637568

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized tomography
Description: Obtained CT scans involving the head region were analyzed retrospectively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized tomography
Description: Obtained CT scans involving the head region were analyzed retrospectively.
Study: NCT03416868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory voice biofeedback
Description: Patients will be provided cues regarding their vocal behavior in daily life. Specifically, the patient will receive 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly. The specific objective voice measure for biofeedback will depend upon which measure is most strongly associated with improvements during voice therapy.
Study: NCT02989493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01950416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg loading dose and 90mg bid maintenance dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 600mg loading dose and 150mg maintenance dose
Study: NCT01710345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab 20 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab 30 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NanoTab
Study: NCT03982901

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Mental Stress Test
Description: In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mental Stress Test
Description: In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
Study: NCT04475081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: Merck MMR-II vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MMR vaccine
Description: Merck MMR-II vaccine
Study: NCT04479397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet Surgery for anterior shoulder instability
Description: Bone block procedure for anterior shoulder instability

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet Surgery for anterior shoulder instability
Description: Bone block procedure for anterior shoulder instability

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No sling in postoperative care
Description: No sling will be used in postoperative care.
Study: NCT05213832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane Inhal Soln
Description: Administration of isofluorane in patients with severe SAH
Study: NCT00704210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpineMed Table, Cert HealthSciences LLC
Description: For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SpineMed Table, Cert HealthSciences LLC
Description: Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
Study: NCT04011540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital data
Description: Receiving digital data prior to a scheduled mental health session
Study: NCT02236026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supratherapuetic dose of Nestorone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study: NCT00774371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy CBT) for weight loss
Description: The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
Study: NCT01245309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scratching
Description: endometrial scratching before COH in IVF

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: A PLACEBO PROCEDURE
Description: A PLACEBO PROCEDURE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A PLACEBO PROCEDURE
Description: A PLACEBO PROCEDURE
Study: NCT01259063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and Intravesical Gemcitabine
Description: Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
Study: NCT05512897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinea plane block
Description: in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
Study: NCT00995761

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Docetaxel and Cisplatin
Description: splitted administration of docetaxel and cisplatin.
Study: NCT04398771

Intervention type: DRUG
Intervention: Rosuvastatin/Valsartan
Description: Rovatitan QD for 12 weeks
Study: NCT01857219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Study: NCT01942928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual NHS Care
Description: Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual NHS Care
Description: Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
Study: NCT03075787

Intervention type: DEVICE
Intervention: standard 24-h ambulatory polysomnography
Description: A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
Study: NCT03043313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given intravenously (into the vein; IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given intravenously (into the vein; IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given orally
Study: NCT02318732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APPS intervention
Description: Contact with and recovery of firearms from individuals who are prohibited from possessing them

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: APPS intervention
Description: Contact with and recovery of firearms from individuals who are prohibited from possessing them
Study: NCT01991808

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT02174965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniHip (Corin U.K.)
Description: MiniHip (Corin U.K.) femoral component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metafix (Corin, U.K)
Description: Metafix (Corin, U.K) conventional cementless stem
Study: NCT01544205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback
Description: 5 sessions lasting one hour each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI-based neurofeedback
Description: 5 sessions lasting one hour each
Study: NCT04426734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dextenza Dexamethasone Implant
Description: The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone Acetate 1%
Description: Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30
Study: NCT02928679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Study: NCT01292135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg daily
Study: NCT03330925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastiMed's SACS
Description: A wearable medical device that improve circulation using smart materials
Study: NCT02425410

Intervention type: OTHER
Intervention: Collect of data on viral environment of T1D patients
Description: Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data

Intervention type: GENETIC
Intervention: Collect of blood samples for DNA extraction and genetic characterization (GWAS)
Description: Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
Study: NCT03945383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with IPL device
Description: Treatment with IPL device
Study: NCT01102114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX Vaccine
Description: NicVAX vaccine given 6 times over 6 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine given 6 times over 6 months
Study: NCT01739998

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: functional oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03052790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manually instrumented total knee arthroplasty
Description: Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic assisted total knee arthroplasty
Description: Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
Study: NCT04146181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
Study: NCT02015273

Intervention type: DEVICE
Intervention: easypod™
Description: Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
Study: NCT01897025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real-tDCS with MI-BCI
Description: As in Arm Description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real-tDCS with MI-BCI
Description: As in Arm Description
Study: NCT03969381

Intervention type: RADIATION
Intervention: diffusion weighted magnetic resonance image in lymphoma
Description: compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
Study: NCT02947893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s) Once a Day by Mouth
Description: 1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib Capsule(s) Once a Day by Mouth
Description: 1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months